Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by mercedesmanon Jan 30, 2023 5:48pm
154 Views
Post# 35255019

RE:RE:RE:RE:Ronco et al Aug 2022 seems to still be pro-PMX (golden hr)

RE:RE:RE:RE:Ronco et al Aug 2022 seems to still be pro-PMX (golden hr) Hmmmm

Disingenuous to imply the next 40 will be enrolled at the rate of one patient per month (or even two) - given the possiblity of 20 + sites, RSV & Covid waning etc.  I'm willing to see what happens Q1 and Q2

Didn't say stoppage at 90 was a given.  Only VERY possible IMO.

Management HAS let Shareholders down (there I said it ...happy ?....actually I have said it many, many times, but you were not listening)

Didn't say investors should invest more...only said that buying more was one of the few ways to protect onself from nasty effects of dilution.  I use the strategy a fair bit,  not just for Spectral.  Often works out very well.

Loss of control of Dialco (really 20% distirbution rights for US) does not equate to a loss of the asset or a potential for a large payback (in various forms, including a reduced need to bring it to the next level, relative to their partner Infomed, or perhaps enhanced rights - ie.g. no finite end to DA)

MM
<< Previous
Bullboard Posts
Next >>